REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer (REAL3)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00824785 |
Recruitment Status :
Terminated
(Lack of efficacy)
First Posted : January 19, 2009
Last Update Posted : December 11, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Oesophago-gastric Cancer | Drug: epirubicin, oxaliplatin, capecitabine (EOX) Drug: EOX + panitumumab | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 574 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer |
Study Start Date : | May 2008 |
Estimated Primary Completion Date : | February 2013 |
Estimated Study Completion Date : | February 2013 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Arm A EOX
EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
|
Drug: epirubicin, oxaliplatin, capecitabine (EOX)
epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21 |
Active Comparator: Arm B EOX + panitumumab.
EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
|
Drug: EOX + panitumumab
epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days |
- Overall survival [ Time Frame: Early termination ]Study closed early due to lack of efficacy
- response rate, toxicity, quality of life and PFS [ Time Frame: Early termination ]Study closed early due to lack of efficacy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically verified inoperable locally advanced or metastatic adenocarcinoma or undifferentiated carcinoma of the oesophagus, oesophago-gastric junction, or stomach.
- Slides of tumour tissue should be available for centralised EGFR staining
- Uni-dimensionally measurable disease (CT or MRI as per RECIST).
- No prior chemotherapy including previous adjuvant chemotherapy
- No prior radiotherapy including adjuvant radiotherapy. Patients receiving palliative radiotherapy to sites of disease that are not measurable may be eligible and should be discussed with the Chief Investigator.
- Male/female patients aged ≥18 years.
- WHO Performance status 0, 1 or 2.
- Patients should have a projected life expectancy of at least 3 months.
- Completion of baseline quality of life questionnaire (EORTC QLQ C30).
- Adequate cardiac function; formal measurement of left ventricular ejection fraction is only required if clinically indicated.
- Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5x109/l; white blood cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can be post-transfusion).
- Adequate renal function: calculated creatinine clearance ≥50ml/minute.
- Adequate liver function: serum bilirubin ≤1.5x ULN; ALT/AST ≤2.5x ULN; ALP ≤3x ULN (in the absence of liver metastases). If liver metastases are present, serum transaminases ≤5x ULN are permitted.
- Written informed consent must be obtained from the patient before any study-specific procedures are performed (see Section 12.0).
Note: Epidermal growth factor receptor (EGFR) positivity by immunohistochemistry will not be required for study entry. Slides obtained from previously collected paraffin embedded archived specimens will be collected centrally for EGFR staining. A multivariate analysis will then be performed to exclude any effects of EGFR status on outcome measures
Exclusion Criteria:
- Tumours of squamous histology.
- Patients with locally advanced oesophageal cancer suitable for definitive chemoradiotherapy.
- Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease.
- Previous chemotherapy or radiotherapy. See Inclusion criteria for note regarding palliative radiotherapy.
- Any major surgery within 4 weeks prior to the start of study treatment.
- Any prior treatment with an EGFR signal transduction directed therapy.
- Treatment with non-permitted medication.
- Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, uncontrolled cardiac dysrhythmia, or myocardial infarction within the last 12 months. Patients with any history of clinically significant cardiac failure are excluded from study entry.
- History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.
- Known peripheral neuropathy >Grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).
- Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication (administration of capecitabine by naso-gastric or jejunostomy feeding tube is permitted).
- Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- Known hypersensitivity to panitumumab, components of the EOX regimen, or any of the constituents of these agents.
- Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic active hepatitis B infection.
- Other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial.
- Female patients who may be pregnant or breastfeeding. Potential female patients of childbearing potential must have a negative pregnancy test within 7 days prior to randomisation, or have had amenorrhea for more than 2 years.
- Patients of child-bearing potential not consenting to use adequate contraceptive precautions or abstinence during the course of the study and for 6 months after the last study drug administration for females, and 1 month for males.
- Any other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
- Treatment with another investigational agent within 30 days of commencing study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824785
United Kingdom | |
Bournemouth | |
Bournemouth, United Kingdom | |
St Luke's Guildford | |
Guildford, United Kingdom | |
Royal Liverpool | |
Liverpool, United Kingdom | |
Royal Marsden NHS Foundation Trust | |
London, United Kingdom, SW3 6JJ | |
Newcastle | |
Newcastle, United Kingdom | |
Royal Marsden NHS Foundation Trust | |
Sutton, United Kingdom | |
Clatterbridge Oncology Centre | |
Wirral, United Kingdom |
Principal Investigator: | Prof Cunningham, David | Royal Marsden NHS Foundation Trust |
Responsible Party: | Professor David Cunningham, Head GI & Lymphoma Units, Royal Marsden NHS Foundation Trust |
ClinicalTrials.gov Identifier: | NCT00824785 |
Other Study ID Numbers: |
CCR3024 |
First Posted: | January 19, 2009 Key Record Dates |
Last Update Posted: | December 11, 2012 |
Last Verified: | December 2012 |
epirubicin oxaliplatin capecitabine panitumumab |
Stomach Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Capecitabine Oxaliplatin Epirubicin |
Panitumumab Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antineoplastic Agents, Immunological |